awmsg logo



darunavir (Prezista®) once daily


Reference No. 1336

Publication date:
13/08/2012


Last review date:
30/08/2016

Appraisal information

darunavir (Prezista®) once daily film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 12/06/2012
AWMSG meeting date: 18/07/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1812
Ministerial ratification: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Darunavir (Prezista®) 800 mg once daily, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count ≥100 cells x 10⁶/l.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download